MedBeat is happy to announce that it has closed an investment round of 9.2 MSEK. This investment round was headed by Danish-based investor Sagitta Ventures, renowned for their extensive experience in effectively growing MedTech companies. Both previous and new investors, including family offices and private investors, also participated in the investment round.
" We at Sagitta Ventures, are truly excited about our investment in MedBeat and look forward to being part of the journey. We think MedBeat has the drive and capability to change the state of cardiac healthcare and they are leading a worldwide trend. MedBeat as an investment matches Sagittas strategy to invest in, and help startup and scaleup companies grow and realising their potential” - says Kim Nielsen, Chief Investment Officer at Sagitta Ventures.
" We are happy to join as investors for MedBeat, a product that will help many in early diagnostics of arrhythmias and heart rhythm disease through their VIVO device. " - Claes Dinkelspiel, investor.
For the past year, MedBeat has continued to grow its sales in over 7 regions within Sweden, partnering with healthcare clinics to offer their VIVO to over 30 000 patients in Sweden.
” Our goal for next year is to continue scaling our sales to more healthcare clinics in Sweden and abroad.” - Erik Rask, founder and CEO.
MedBeat, founded in 2018, is a leading Medtech company specializing in the development of next-generation cardiac medical devices for both healthcare and private individuals. By offering an innovative solution for continuous measurement of heart rhythm through their VIVO device, the company aims to reduce the incidence of stroke and sudden cardiac death globally.
+46 70 443 34 47 External links: https://rapidus.se/2023/12/20/finansman-gar-in-i-medbeat/